Our group is interested in the development of antibody-based therapeutics for cancer. The research focuses on engineering of monoclonal antibodies, bispecific antibodies, or chimeric antigen receptors (CARs) to treat tumors. We identify novel human monoclonal antibodies from antibody phage libraries. Monoclonal antibodies typically IgGs can destroy tumor cells by utilizing mechanisms of antibody-dependent cellular cytotoxicity (ADCC) or antibody-drug conjugation (ADC). By using these antibodies as vehicles, bispecific antibodies directed at tumor antigens and human CD3 can engage T cells to lyse tumors. Additionally, all of these antibodies can be reshaped to build CAR to redirect T cells.
Areas of Expertise:
(1) antibody engineering; (2) CAR-modified T cells ; (3) antibody-drug conjugation; (4) phage and yeast display libraries